Tonix Pharmaceuticals stock halted ahead of FDA approval news
Viatris Inc (NASDAQ:VTRS) Chief Executive Officer Smith Scott Andrew reported purchasing 22,000 shares of the company’s common stock on August 12, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were bought in a range of $9.68 to $10.12, with a weighted average price of $9.9882, totaling $219740.
Following the transaction, Smith directly owns 314,807 shares of Viatris. The purchase was disclosed in a Form 4 filing signed by Kevin Macikowski, by power of attorney, on August 13, 2025.
In other recent news, Viatris Inc. reported its second-quarter earnings for 2025, exceeding analyst expectations with an earnings per share of $0.62, compared to the projected $0.55. The company also surpassed revenue forecasts, reporting $3.57 billion against an anticipated $3.47 billion. These results have contributed to a positive outlook among investors. Additionally, the U.S. Food and Drug Administration approved Viatris’ Iron Sucrose Injection, USP, marking the first generic version of Venofer Injection. This intravenous iron replacement product is used to treat iron deficiency anemia in patients with chronic kidney disease and will be available in three different strengths. The approval of this generic medication represents a significant development for the company. These recent developments highlight Viatris’ progress in both financial performance and product offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.